Abbreviation
HLA-I: human leukocyte antigen class I; HLA-I LOH: loss of heterozygosity in human leukocyte class I; WES: whole exome sequencing; TMB: tumor mutation burden; MSI: microsatellite instability; DDR: DNA damage response; CPF: check point factor; FA: Fanconi anemia; ICI: immune checkpoint inhibitor; PD-L1: programmed cell death-ligand 1; MHC-I: major histocompatibility complex class I; NK cell: natural killer cell; SqCC: squamous cell carcinoma; BRCA: breast invasive carcinoma; CESC: cervical squamous cell carcinoma and endocervical adenocarcinoma; CRC: colorectal carcinoma; KIPAN: pan-kidney cohort; LIHC: liver hepatocellular carcinoma; LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; NSCLC: non-small cell lung cancer; OV: ovarian serous cystadenocarcinoma; PAAD: pancreatic adenocarcinoma; PRAD: prostate adenocarcinoma; STES: stomach and esophageal carcinoma; UCEC: uterine corpus endometrial carcinoma.